Overview

• Published today in Nature Medicine, the CLEVER randomized phase II trial enrolled 51 survivors and cleared minimal residual disease in about 80% within 6 to 12 months.
• Three-year recurrence-free survival exceeded 90% for patients on single-drug therapy and reached 100% for those who received both drugs.
• After a median follow-up of 42 months, only two participants have experienced a recurrence.
• The study used FDA-approved drugs that act on autophagy and mTOR pathways, though investigators did not disclose the specific agents.
• Larger confirmatory phase II studies, ABBY and PALAVY, are now enrolling at multiple cancer centers.